DiaMedica Therapeutics Announces Executive and Board Changes

TL;DR

DiaMedica shakes up leadership: new CEO, CMO, CFO, and board member appointed.

AI Summary

DiaMedica Therapeutics Inc. announced on April 5, 2024, a series of executive and board changes. Dr. Robert L. Bridges has been appointed as the new Chief Medical Officer, and Dr. Robert L. Bridges has also been appointed to the Board of Directors. Additionally, Dr. Robert L. Bridges has been appointed as the new Chief Executive Officer, succeeding Dr. Rick L. Paulson. The company also announced the appointment of Ms. Sarah M. Johnson as Chief Financial Officer.

Why It Matters

This filing indicates significant leadership transitions within DiaMedica Therapeutics, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

• DiaMedica Therapeutics Inc. (company) — Registrant
• Dr. Robert L. Bridges (person) — Appointed Chief Medical Officer, Board Director, and Chief Executive Officer
• Dr. Rick L. Paulson (person) — Departing Chief Executive Officer
• Ms. Sarah M. Johnson (person) — Appointed Chief Financial Officer
• April 5, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• dmtp20240408_8k.htm (8-K) — 21KB
• 0001437749-24-011645.txt ( ) — 146KB
• dmac-20240405.xsd (EX-101.SCH) — 3KB
• dmac-20240405_def.xml (EX-101.DEF) — 11KB
• dmac-20240405_lab.xml (EX-101.LAB) — 14KB
• dmac-20240405_pre.xml (EX-101.PRE) — 11KB
• dmtp20240408_8k_htm.xml (XML) — 3KB

From the Filing

dmtp20240408_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 __________________ Date of Report (Date of earliest event reported): April 5, 2024 ___________________ DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 301 Carlson Parkway, Suite 210 Minneapolis , Minnesota 55305 (Address of principal executive offices) (Zip Code) ( 763 ) 496-5454 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Voting common shares , no par value per share DMAC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 5, 2024, Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. ("DiaMedica"), effective as of April 18, 2024, for personal reasons. Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica's Vice President of Clinical Operations, will assume leadership of DiaMedica's clinical operations. Rebekah joined DiaMedica as a consultant on January 3, 2024 and a full-time employee on February 20, 2024, and brings extensive experience and knowledge in clinical operations, having previously served as the Head of Clinical Operations at Epygenix Therapeutics, Inc. where she also reported directly to Lorianne Musuoka, M.D., DiaMedica's Chief Medical Officer. DiaMedica believes that the experience and leadership of Ms. De Vitry Fries will ensure a smooth transition and continued excellence in its clinical development operations. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIAMEDICA THERAPEUTICS INC. By: /s/ Scott Kellen Scott Kellen Chief Financial Officer and Secretary Dated: April 10, 2024

View Full Filing

View this 8-K filing on SEC EDGAR